-
ESMO News: Innovative tumor therapy TILs cell therapy is coming, and clinical trials have been carried out
Time of Update: 2022-10-03
org/meetings/esmo-congress-2022Click below to learn more about clinical trial programsWhen it comes to immunotherapy, people generally think of PD-1 or PD-L1 inhibitors, but immunotherapy includes a wide range of treatments, such as tumor-infiltrating lymphocyte (TILs) therapy.
-
This common thyroid problem does not require immediate treatment for the vast majority of older adults
Time of Update: 2022-05-02
Subclinical hypothyroidism (hypothyroidism) is one of the most common endocrine diseases in clinical practice, and is mainly characterized by a markedly elevated serum thyrotropin level (usually ≥4. 5
-
Cureus: Treatment of severe neutropenic Graves disease
Time of Update: 2022-04-20
ATDS is an effective and safe therapy for the treatment of hyperthyroidism in GD, but contraindications and adverse effects may limit its use, including severe neutropenia, a well-known adverse effect of ATDS, in the treatment of hyperthyroidism may occur during the course of the disease and treatment should not be initiated when the absolute neutrophil count (ANC) is <1x109/L .
-
JAMA Xi'an Jiaotong University cooperated with multiple units, Wu Jing/Wang Youfa revealed that the incidence of diabetes and prediabetes in China has exceeded 50
Time of Update: 2022-01-27
On December 28, 2021, Wu Jing from the Chinese Center for Disease Control and Prevention and Wang Youfa from Xi'an Jiaotong University published a research paper titled "Prevalence and Treatment of Diabetes in China, 2013-2018" online in the top international medical journal JAMA (IF=56).
-
JCO: Capecitabine + chemotherapy can prolong the survival of patients with early breast cancer; this traditional Chinese medicine is approved for first-line treatment of liver cancer indications
Time of Update: 2022-01-25
(If you want the original text of the document, you can add Xiaobian WeChat yxj_oncology to get it) Key points: Lancet Oncol: O drug + cabozantinib combination therapy can improve progression-free survival and improve patient-reported outcomes JCO: Add capecitabine on the basis of adjuvant chemotherapy A new drug that can prolong the survival of patients with early breast cancer: traditional Chinese medicine for liver cancer!
-
Good news for patients with metastatic cancer of unknown primary tumor (R) may bring therapeutic benefits
Time of Update: 2022-01-01
is a microarray-based gene expression detection product that can assist in evaluating metastasis The origin of poorly differentiated and undifferentiated tumors in order to improve the treatment benefit of patients with metastatic carcinoma of unknown primary (CUP) .
-
Soybean imports plummeted by 40%, Henan Association guides feed price increase by 75-100
Time of Update: 2021-12-08
Soybean imports fell to the lowest level in 7 monthsLYM China Feed Industry Information Network-Based on feed, serving animal husbandry On November 7, the data released by the General Administration of Customs showed that China's grain imports in October were 9.
-
Stroke: Delirium after a stroke, what changes in the brain network
Time of Update: 2021-10-20
Little is known about ARAS and the function of attention and orientation networks in stroke patients at risk of SN and delirium.
To assess the relationship between the global functional connectivity of the four right hemibrain seed areas in the cortical-subcortical arousal and attention network and effective measures of SN and delirium severity .
-
Express treatment of ovarian cancer and triple-negative breast cancer, innovative ADC therapy entered the clinic
Time of Update: 2021-10-11
▎The content team editor of WuXi AppTec today, ADC Therapeutics announced that its antibody-conjugated drug (ADC) ADCT-901, which targets kidney-associated antigen 1 (KAAG1), has completed the first patient administration in a phase 1 clinical trial.
-
2021 CSCO Professor Qiu Lugui and Professor Fu Weijun work together to interpret the wonderful performance of selinexor in the treatment of multiple myeloma
Time of Update: 2021-10-10
Today at 12:20, Selinexor (ATG-010) combined with low-dose dexamethasone in the treatment of relapsed and refractory multiple myeloma (R /R MM) The results of the MARCH study of patients were announced by Professor Fu Weijun to medical professionals nationwide in ORAL format .
-
The world's first innovative drug for the treatment of PIK3CA mutant breast cancer, Alpelisib, is introduced to Boao
Time of Update: 2021-08-28
As the world’s first and currently the only oral drug approved overseas for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, and PIK3CA mutant advanced breast cancer, Novartis Alpelisib has been approved for specific use in the Hainan Pilot Zone The application of medical institutions to urgent clinical needs fills the gap in this field in China and brings hope to patients in urgent need of treatment .
-
How is PPP syndrome diagnosed
Time of Update: 2021-06-01
10 mg/L; Immune indicators: ANA+dsDNA+ENA, ANCA, anti-ACL (-); CT of the lung: a little inflammation in the left lingual lobe and right middle lobe; lower limb skin biopsy: "panniculitis" The pathological changes; bone marrow smears: 1.
-
"BOTH China 2019 Technical Seminar" was successfully held
Time of Update: 2021-05-01
Jifeng Yuan, Global CTO of Fire Protection and Building Products and Business Director of Asia Pacific Region of Element Materials Technology, delivered a speech on "Quality Assurance of Reactive Coatings-Current Experience in the UK and Europe".
-
Prostate Cancer Standardized Diagnosis and Treatment Courses——Full-process Standardized Management of Prostate Cancer
Time of Update: 2021-04-28
The fifth "Prostate Cancer Standardized Diagnosis and Treatment Course", the fifth is the "Full-process Standardized Management of Prostate Cancer" brought by Professor Guo Gang from the PLA General Hospital: Click to watch the highlights video!
-
"The Lancet Respiratory Medicine" first published the results of the Chinese original third-generation EGFR-TKI (Vormetinib) treatment for advanced NSCLC led by Professor Shi Yuankai
Time of Update: 2021-04-14
094) published the full text online, led by Professor Shi Yuankai from the Cancer Hospital of the Chinese Academy of Medical Sciences, the original third-generation EGFR- TKI vometinib (furmonertinib/AST2818, formerly known as: alflutinib [alflutinib]) in the treatment of patients with EGFR T790M mutation advanced non-small cell lung cancer (NSCLC) Phase IIb clinical study (NCT03452592) results1.
